## REMARKS

Claims 1-117 are canceled without prejudice or disclaimer. Claims 118-179 are added. Claims 118-179 are supported by the specification and claims as originally filed, including at pages 6, 17, 24-26 and original claims12-18. There is no new matter added, and entry of the amendment is respectfully requested.

Applicants also enclose herewith a copy of the Declaration of Torben V. Borchert, previously submitted in parent application, USSN 10,025,648, which was recently allowed. The nucleic acids (and methods of producing alpha-amylase variants using the nucleic acids) claimed in the instant application encode alpha-amylase variants subject to the Borchert Declaration.

A new paper copy of the Sequence Listing is submitted. The computer-readable form in this application is identical with that filed in application no. 08/600,656, filed February 13, 1996. In accordance with 37 CFR 1.821(e), please use the last filed computer readable form filed in that application as the computer readable form for the instant application. The content of the attached Sequence Listing and of the computer readable form filed in the parent application is the same. Accordingly, there is no new matter added.

Figures 1-5 are added to the specification. Figures 1-5 are taken from parent application, U.S. application 10/025,648, the contents of which were fully incorporated herein by reference. Accordingly, there is no new matter added.

Certified copies of the Danish priority applications were submitted in parent application. U.S. application 10/025,648, filed December 19, 2001. Please acknowledge Applicants claim to priority and receipt of the certified copies of the Danish priority documents.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: February 18, 2005

Jason I. Garbell, Reg. No. 44,116 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110

(212) 840-0097